Earnings
Royalty Pharma CEO Says He Doesn't 'See Any Negatives' Politically, Day After Midterms
Pablo Legorreta pitched a business built to work under any administration as Royalty Pharma lifted its 2026 receipts outlook to $3.5 billion–$3.55 billion.